--- title: 'Software Daily Summary: What Happened on October 15, 2026' headline: HitSV detects structural variants across sequencing types description: Other releases include a 73-million-sequence nanobody database, an open-source developability tool and an update to a manufacturing ontology. url: https://thebench.bio/news/software/2026-10-15 topic: software date: '2026-10-15' covers: - '2026-10-15' date_published: '2026-10-15T12:03:57Z' date_modified: '2026-10-15T12:03:57Z' tags: - Software - Research sources: 5 publisher: TheBench.Bio --- # Software Daily Summary: What Happened on October 15, 2026 **HitSV detects structural variants across sequencing types** Other releases include a 73-million-sequence nanobody database, an open-source developability tool and an update to a manufacturing ontology. ## Today in brief HitSV detected structural variants in short-read, long-read and hybrid sequencing data, expanding the 1000 Genomes Project phase 4 callset by 31.5%. [1] OAS-nano adds 73 million nanobody sequences to a searchable database, while the Therapeutic Nanobody Profiler offers an open-source way to assess nanobody developability. [2] [3] INmune Bio and QCi agreed to use computational tools to search for other potential uses for XPro. [4] ## Also worth knowing - In the HG002 benchmark, HitSV reached genotype F1 scores of 85.00% on 30× PacBio HiFi data and 88.48% on 30× ONT data, beating other evaluated callers by 15.34–71.68%. [1] - OAS-nano contains 73 million natural VHH antibody sequences after deduplication and labels the amplification method used for each dataset. Its authors say it is five times larger than the biggest earlier database using the same redundancy filter. [2] - The Therapeutic Nanobody Profiler compares six nanobody properties with 36 clinical-stage examples. Its software and datasets are open source, and the study examined assay results from 108 nanobodies expressed as IgG constructs. [3] - The Pistoia Alliance released version 1.1 of its CMC Process Ontology, which covers lab- and plant-scale manufacturing and integration points for analytics, materials, equipment and quality. The project team intends to publish a public version on GitHub in November 2026. [5] - INmune Bio and QCi plan to compare QCi’s quantum optimization system with conventional statistical and machine-learning methods. They will use data from four clinical trials and other sources to investigate potential additional uses for XPro. [4] ## The day in numbers - **31.5%**: Expansion of the structural-variant callset after HitSV was applied to the 1000 Genomes Project phase 4 cohort. [1] - **73 million**: Natural VHH antibody sequences in OAS-nano after deduplication. [2] - **108**: Nanobodies with experimental developability assay data assessed alongside the Therapeutic Nanobody Profiler’s guidelines. [3] ## Also published - [The Fundamentals of Omnichannel Still Apply: Q&A with Pat McGloin](), Pharmaceutical Executive - [An Updated Jupyter Notebook for docking](), Mac in Chem ## Sources 1. [Structural variant detection across sequencing technologies](), Nature Biotechnology, 2026-10-15 2. [OAS-nano: New Repertoire Database Just Dropped](), BLOPIG, 2026-10-15 3. [Characterising nanobody developability to improve therapeutic design using the Therapeutic Nanobody Profiler](), BLOPIG, 2026-10-15 4. [QCi and INmune Bio partner to study XPro in Alzheimer’s](), Pharmaceutical Technology, 2026-10-15 5. [The CMC Process Ontology is released. But how do we get scientists to adopt it?](), Pistoia Alliance, 2026-10-15 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: